Background. Excessive inflammation persists despite antiretroviral treatment. Statins decrease cardiovascular (CV) disease risk by reducing low-density lipoprotein cholesterol and inflammation. We performed an exploratory analysis to evaluate whether statin therapy decreased risk of non-AIDS-defining events and nonaccidental death.
of interleukin 6, reduced lymphocyte and monocyte activation, improved nitric oxide synthesis, and anticoagulation effects [13] . Statins decrease T-cell activation in untreated HIV-infected persons and are being evaluated in persons with viral suppression [18] .
We tested the hypothesis that HIV-infected persons reporting statin use have a decreased risk of end-organ disease and nonaccidental death in an exploratory retrospective analysis utilizing the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort (ClincalTrials.gov identifier: NCT00001137) to inform effect size, endpoints of interest, and specific populations for future trial development [19] .
METHODS

Study Population
ALLRT is an observational cohort enrolling HIV-infected persons prospectively randomized to initiate ART, immunebased therapy, or ART strategies within ACTG parent studies [19] . The study was designed to evaluate long-term outcomes associated with ART, thus providing an ideal population to evaluate the effect of statins. After parent protocol completion, ALLRT follow-up continued at 16-week intervals. The June 2009 ALLRT datasets were used for these analyses. ALLRT and parent studies are approved by the institutional review board at each location; participants provide written informed consent for both.
Study Outcomes
The primary aim was to examine the effect of statin use on end-organ disease and nonaccidental death, after ALLRT entry. Outcomes of interest included major cardiovascular, renal or hepatic disease, incident diabetes, stroke, thrombotic event, nontraumatic fracture, non-AIDS-defining malignancy (all cancers excluding Kaposi sarcoma, non-Hodgkin lymphoma, and invasive cervical cancer), serious bacterial infection, or nonaccidental death from any cause similar to those defined in previous studies (Supplementary Appendix) [20] . Given concern regarding time for statins to have an effect and limited precision of statin start and stop dates in the ALLRT database, we excluded events from the 56 days after statin initiation. In a sensitivity analysis, these early events are included to evaluate for bias due to exclusion. In a post hoc analysis, we evaluated whether the impact of statin therapy varied by time since initiation, as well as its effect on AIDS-defining events collected in ALLRT [21] .
Statistical Considerations
We utilized marginal structural model methodology [22, 23] . The hazard ratio (HR) of study outcomes for statin initiation vs noninitiation was estimated with pooled logistic model for risk of study outcomes at a given month, which included a time-varying indicator for use of statins through the preceding month and the following baseline covariates: age, sex, race/ ethnicity, intravenous drug history, history of coronary artery disease, hepatitis B coinfection, systolic blood pressure (BP), estimated glomerular filtration rate (eGFR), serum glucose, low-density lipoprotein (LDL) cholesterol, current use of nonstatin lipid-lowering drugs, HIV type 1 (HIV-1) RNA, CD4 count, current smoking, and waist-to-hip ratio.
Statin initiation is more likely in subjects who smoke and have elevated LDL cholesterol and systolic BP, leading to timedependent confounding by indication. Because these confounders are affected by prior statin use and are on the causal pathway between statins and study outcomes, we used inverse probability of treatment weighting (IPTW) to adjust for measured time-dependent confounders; inverse probability of censoring weighting (IPCW) was used to adjust for potential selection bias due to censoring. Both the statin initiation and censoring weights were stabilized and their products used in the final weighted regression model. Assuming that all timevarying predictors of both statin initiation or censoring and our study outcomes were included in the analyses, the weighted model estimates the parameters of a marginal structural Cox model [22] [23] [24] [25] .
All subjects in the logistic models received a time-varying weight inversely proportional to the probability of having their own observed history of statin initiation and history of censoring. To estimate each subject's probability of statin initiation or censoring at each month, separate pooled logistic models were used including covariates listed above plus the most recent value of time-varying covariates: systolic BP, eGFR, glucose, LDL cholesterol, current use of nonstatin lipid-lowering drugs, HIV-1 RNA, CD4 count, current smoking, and waist-to-hip ratio.
Following intent-to-treat principles, we assumed that subjects remain on statins once initiated. P values <.05 were interpreted as statistically significant. Nominal values were reported without adjustment for multiple comparisons. In a planned secondary analysis, we evaluated study outcomes by covariate stratification to look for a differential effect for baseline covariates. Analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
Of 4641 subjects in the 2009 ALLRT database, 4405 were not on a statin at ALLRT enrollment; 3601 had complete baseline data and were included. Compared to persons with incomplete baseline data, persons included in this analysis had statistically significant lower waist-to-hip ratio, higher glucose, higher eGFR, less use of lipid-lowering drugs (not statins), lower CD4 cell count, lower Framingham risk score, later year of parent study entry, shorter time from parent study entry to ALLRT entry, and greater use of ART (data not shown).
At ALLRT entry, the study population was 83% male, 47% non-Hispanic white, 30% non-Hispanic black, and 21% Hispanic; 38% were current smokers, 21% had preceding AIDSdefining events; and median nadir and baseline CD4 counts were 180 cells/mm 3 and 346 cells/mm 3 , respectively. Median LDL cholesterol was 106 mg/dL with 73% having a value <130 mg/dL. The median time from parent study entry to ALLRT entry was 16 weeks. Overall, 95% of persons were on ART (38% protease inhibitor based, 39% nonnucleoside reverse transcriptase inhibitor based, 23% other) with 66% having plasma HIV-1 RNA <400 copies/mL. Other baseline parameters are listed in Table 1 .
Over 15 135 years of follow-up, 481 subjects initiated a statin (54% atorvastatin, 35% pravastatin, 11% other). As expected, certain baseline parameters (male sex, older age, higher LDL cholesterol, history of cardiovascular [CV] endpoint) and time-varying covariates (higher systolic BP, glucose, LDL cholesterol, waist-to-hip ratio, use of nonstatin lipid-lowering drugs, lower plasma HIV RNA level, higher CD4 + T-cell count) were independently associated with a greater probability of statin initiation (P < .05 for all). The median (Q1, Q3) duration of follow-up since statin initiation in this cohort was 2.8 years (1.6, 4.9). A total of 616 first non-AIDS events were observed (Table 2) To evaluate whether the observed statin effect was driven primarily by CV events, we repeated the analysis with these events removed and by individual event categories (Table 3) . Consistent results were observed for CV events (AHR, 0.89 [95% CI, .32-2.44]) and non-CV events (AHR, 0.85 [95% CI, .56-1.31]). For the individual event categories of mortality, incident diabetes, and renal events, effect sizes of a similar magnitude to the overall effect were observed. Statin use was associated with a higher rate of bacterial infections (AHR, 1.25 [95% CI, .62-2.51]) and had a protective effect for malignancy of greater magnitude than the observed overall effect (AHR, 0.43 [95% CI, .19-.94]). With the exception of the analysis restricted to malignancies, the 95% CIs for all estimated effects include an HR of 1.
In planned subgroup analyses, evidence of a differential statin effect by baseline characteristics was evaluated ( Figure 2 ). Although no differential effects were detected (P value for interaction >.1), some interesting trends were observed. For example, the estimated beneficial effect of statins increased with higher nadir CD4 + T-cell count, older age, among females, and among black non-Hispanics. To assess for bias by excluding events in the 56 days after statin initiation, we performed sensitivity analyses. Eight Table 4 ).
In a post hoc analysis, the AHR was estimated as a function of time since statin initiation, utilizing a 3-level time-varying indicator (ie, no statin, <2 years after initiation, ≥2 years after initiation). Although the AHR was not statistically different (P = .20) by category, there was a shift in effect (<2 years: 0.96 [95% CI, .58-1.59]; ≥2 years: 0.63 [95% CI, .37-1.06]). We also assessed the impact of statin initiation on AIDS-defining events. There were 172 AIDS-defining events, with Pneumocystis jirovecii pneumonia (n = 31), esophageal candidiasis (n = 26), disseminated mycobacterial infection other than tuberculosis (n = 17), wasting syndrome (n = 17), Burkitt lymphoma (n = 16), and cryptosporidiosis (n = 16) being the most common ( 
DISCUSSION
Overall, statin use was associated with a 19% reduction in non-AIDS events and nonaccidental mortality, although this finding was not statistically significant. Most striking was a 57% reduction in malignancy risk associated with statin use. The beneficial effects of statins were not driven specifically by CV events, providing plausibility that statins have important anti-inflammatory properties providing benefit beyond CV prevention. However, for serious bacterial infection, statins were associated with a nonsignificant 25% increased risk.
Interestingly, event rates for non-AIDS events were nearly 4 times higher than for AIDS-defining events (4.1 vs 1.1 per 100 PY). The higher incidence of non-AIDS-defining events supports other reports that non-AIDS events are increasingly relevant [26] . Palella et al reported a marked shift in causes for mortality: AIDS-related mortality declined from 54% to 25% and non-AIDS causes increased from 13% to 43% between 1996 and 2004 [27] . From the Strategies for Management of Antiretroviral Therapy (SMART) and Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) studies, similar findings have been reported: serious non-AIDS events occurred nearly 50% more frequently than AIDS-defining events, with a demonstrably higher mortality rate at 6 months for non-AIDS-related causes (13% vs 5%) [28] .
The differences in risk for endpoint categories are intriguing. Notably, the risk for bacterial infections and AIDS- defining events appeared to be increased with statin initiation. It is possible that this association was driven by nonadherence to both HIV and statin therapy and thus progressive HIV disease, but it is certainly possible that statin-induced reductions in innate immune activation might have beneficial effects on some morbidities, yet harmful effects on clearance Figure 2 . Differential effect by baseline covariates. Abbreviations: BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HIV-1, human immunodeficiency virus type 1; HR, hazard ratio; IV, intravenous; LDL, low-density lipoprotein. of infections in the setting of immunodeficiency. Previous reports in HIV-uninfected persons have suggested that bacterial infections, particularly bacterial pneumonia, are reduced with statin therapy mediated through reduction in immune activation and inflammatory cytokines [29] . The effects of statins may serve to attenuate an overexuberant immune response to pathogens. Future research should explore whether the depletion of CD4 cells with HIV infection may alter the signaling pathways through which statins affect immune surveillance and negatively impact infections [13, 30] . In the geriatrics literature, immunosenescence contributes to progression of end-organ disease, characterized by a proinflammatory state manifested by a phenotype of T-cell exhaustion, elevated proinflammatory cytokine levels, and poor responses to recall or neoantigens [31, 32] . This shift contributes to functional decline with accrual of comorbidities and increased mortality. HIV infection causes persistent inflammation and T-cell activation with a heightened risk for non-AIDS comorbidities [4] . In the pre-highly active antiretroviral therapy era, Giorgi et al demonstrated that T-cell activation contributes significantly to mortality [33] . Subsequent data from numerous groups have demonstrated that ART reduces the level of inflammation and T-cell activation to some degree but incompletely [1, 34] . The residual proinflammatory state is associated with end-organ disease and mortality [2] [3] [4] 35] . Recently published data demonstrated that atorvastatin significantly reduced T-cell activation in untreated HIV-infected persons, similar to previous reports in HIV-uninfected persons [19, 36] .
Another retrospective analysis highlighted a 3-fold reduction in hazard of death in individuals with suppressed viremia who received a statin [37] . In our analysis, we reported very similar results after adjusting for baseline parameters, demonstrating a 59% reduction in mortality (AHR, 0.41). After the weighting for time-varying covariates, the AHR shifted to 0.82, indicating an 18% reduction.
Another observational study demonstrated a 45% reduction in risk of non-Hodgkin lymphoma for those individuals who received a statin [38] . These data are consistent with our data, which demonstrated a 57% reduction in malignancies. For many malignancies, inflammation and altered immune function are important contributors, and in the case of HIV have been linked to the incidence of lymphoma [39, 40] . Although it is difficult to generalize given the broad number of cancers included in this analysis, recognition that immune dysfunction and persistent inflammation may contribute to development of malignancies speaks to the need to investigate preventative therapies to abrogate the development of these events. Although reduction in overall events did not reach statistical significance, these data inform future trial development. In particular, identifying event rates and effect size in particular demographic groups from this analysis will influence future trials. For instance, statin therapy modestly reduced events in persons <30 years of age (19% reduction) whereas persons >50 experienced a 51% reduction of non-AIDS events. Given that non-AIDS event rates are higher in older persons, a meaningful result could be achieved with a smaller sample in that particular population. For example, limiting a study to include HIV-infected persons >45 years with LDL cholesterol <130 mg/dL (in whom the event rate was 8.2/100 PY in this analysis), a sample size of 2900 participants would provide 90% power to detect a 20% reduction in events. This 20% reduction would be highly relevant, as the number needed to treat to prevent 1 event over 5 years would be 17.
The current analysis has certain limitations. To address the potential for confounding by indication, which inherently biases treatment effects detected in observational trials, we utilized marginal structural modeling (MSM). Treatment and censoring weights were used to create a pseudopopulation whereby the probability of initiating a statin or being censored was unrelated to measured time-dependent confounders. As these time-dependent confounders are controlled for by the weights rather than by inclusion as covariates, we minimize the concern that these confounders serve as intermediates on the causal pathway from statin initiation to study outcomes. MSM attempts to estimate the causal effect of statins, rather than simply present associations, based upon certain assumptions. First, the methodology assumes that no unmeasured confounding was present and thus the inverse probability weights adjust for both confounding and selection bias. This assumption relies on accurate data on all time-dependent confounders. We acknowledge that this untestable assumption may not fully hold and some residual unmeasured confounding may exist. However, the baseline and time-varying covariates, which were identified as independently associated with statin initiation, are the factors we would expect to identify in this population. Second, the methodology assumes that reporting of statin initiation and study outcomes are accurate. Although data for common CV risk factors (smoking status, fasting lipid panel, and BP) were prospectively collected at ALLRT visits, data for other parameters were not collected, such as antiplatelet therapies or cytomegalovirus status. Also, because our analyses are restricted to data collected after ALLRT enrollment, underreporting for some events may have occurred due to recall bias. Additionally, the set of covariates we used to address confounding may not be the minimal set needed. Adjusting for too many covariates may introduce bias or substantially increase the variance of the treatment effect while adjusting for too few may not fully resolve the issue of confounding [25] . Also, 18% of potential ALLRT subjects with missing baseline data were not included. Of the 3601 subjects included in the analysis population, 616 (17%) first events were reported; for the 804 subjects not included, there were 158 (20%) first events. Additionally, 13% of the analysis subjects initiated a statin, whereas 20% of subjects not included initiated a statin. It is difficult to speculate whether exclusion of these 804 subjects may have biased our results, if at all, due to the reliance of the treatment and censoring weights on baseline data. In the absence of a randomized clinical trial, and despite these limitations, we believe that the use of MSM methodology within the ALLRT cohort provides the optimal opportunity to estimate the causal effect of statin initiation.
Exclusion of early events was aimed at preventing misclassification due to challenges with reporting events and the exact timing of statin initiation. We recognized the potential impact on our results and performed a sensitivity analysis to include early events. Eight events were identified and included in this analysis, some of which were reported within days of statin initiation. The inclusion of these events caused minor shifts in AHR point estimates and 95% CIs. Results were not markedly different from the initial analysis, indicating that results are not overly biased by timing of events.
We were potentially underpowered to detect all but large statin effects. In preparation for the analysis, we estimated that with 4500 persons, of whom 30% initiated a statin, and an event rate of 1.9 per 100 PY in the nonstatin group, we would have 80% power to detect a 26% difference in event rates. In the restricted cohort with complete baseline data that was ultimately included, only 13% initiated a statin. Although the observed event rate in the nonstatin group was higher than anticipated (4.0 per 100 PY), this reduction in sample size and the loss of efficiency associated with the weighting likely contributed to the wide confidence intervals seen.
In summary, statins were associated with a 19% reduction in non-AIDS events and nonaccidental death that was not statistically significant. Malignancies were the only endpoint for which a statistically significant reduction in event rate was observed. The benefits of statins were more apparent in the older population. Our results inform the future development of properly sized prospective clinical endpoint trials to reduce residual inflammation despite ART and limit the development of non-AIDS comorbidities.
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